Scientific Reports 6: Article number: 32103 10.1038/srep32103; published online: September 02 2016; updated: March 24 2017
The original version of this Article contained an error in the Abstract.
“While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.
now reads:
“While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.
This error has now been corrected in the PDF and HTML versions of the Article.